This issue reminds us that humankind remains the enduring question, and diversity in clinical trials is the answer (even if ...

Johnson & Johnson has reported late‑breaking phase 2 results showing that nipocalimab met the primary endpoint of reducing ...

JJP Biologics has reported positive interim findings from its ongoing phase 1b study of nebaprubart (JJP‑1212) in patients with linear IgA disease, a rare autoantibody‑driven blistering disorder with ...

Deep Science Ventures (DSV) and Medicines Discovery Catapult (MDC) have formed a strategic partnership to tackle one of ...

Aragen has completed the technology transfer and first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead ...

Resolution Therapeutics has welcomed new four‑year follow‑up data from the University of Edinburgh’s MATCH trial, which ...

Pierre Fabre Laboratories has received a positive opinion from the European Medicines Agency’s CHMP recommending approval of ...

Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered ...

Microbiotica has announced positive findings from its phase 1b MELODY‑1 trial of MB097, an oral precision microbiome co‑therapy being developed for advanced melanoma. The study met all primary and ...

Novo Nordisk has presented new sub‑analyses from the phase 3 OASIS 4 trial at ECO2026, showing that oral semaglutide 25mg tablets delivered substantial weight loss and improvements in mobility for ...

Enterprise Therapeutics has reported that its phase 2 trial of ETD001, an investigational inhaled epithelial sodium channel blocker, met its primary efficacy outcome in people with cystic fibrosis who ...

Poolbeg Pharma has received formal notification that its patent covering the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy‑induced cytokine release ...